The regulatory function of Ikaros and CK2 on SHIP1 expression in B-ALL highlights the relevance of the AKT pathway as a therapeutic target for the treatment of this disease. The gene discussed is AKT1; the disease is precursor B-cell acute lymphoblastic leukemia.